NCT03674411: Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
- State
- Under way
- Phase
- Phase 2
- People
- 22 taking part
- Started
- 2 Jan 2019
- Primary completion
- 23 Jun 2020
- Arms
- BU,FLU, MEL + MGTA-456 infusion
- Results
- Posted on the registry
- 17 Sep 2018: Trial registered
- 2 Jan 2019: Trial started
- 30 Jan 2024: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Percentage of Participants With Neutrophil Recover
Primary outcome · Number, Percentage of participants · Day 14
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 31 (95% Confidence Interval 14 to 60) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 50 (95% Confidence Interval 9 to 99) |
Number of Days Alive Without Hospitalization
Secondary outcome · Median, Days · Day 0 and Day 100
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 67.5 (Full Range 18 to 85) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 33 (Full Range 0 to 66) |
Secondary Graft Failure
Secondary outcome · Number, Percentage of participants · 2 Years
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 37.5 |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 |
Platelet Recovery
Secondary outcome · Number, Percentage of participants · Day 42
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 56 (95% Confidence Interval 33 to 80) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 50 (95% Confidence Interval 1 to 99) |
Treatment Related Mortality (TRM)
Secondary outcome · Number, Percentage of participants · 6 Months
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 6 (95% Confidence Interval 0 to 18) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 50 (95% Confidence Interval 15 to 85) |
Grades II-IV Acute GVHD
Secondary outcome · Number, Percentage of participants · Day 100
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 25 (95% Confidence Interval 4 to 46) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 (95% Confidence Interval 0 to 100) |
Grades III-IV Acute GVHD
Secondary outcome · Number, Percentage of participants · Day 100
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 19 (95% Confidence Interval 0 to 37) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 (95% Confidence Interval 0 to 100) |
Chronic GVHD
Secondary outcome · Number, Percentage of participants · 1 Year
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 13 (95% Confidence Interval 0 to 28) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 (95% Confidence Interval 0 to 100) |
Relapse
Secondary outcome · Number, Percentage of participants · 2 Years
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 25 (95% Confidence Interval 4 to 46) |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 50 (95% Confidence Interval 1 to 99) |
Non-catheter Associated Bacterial Infections
Secondary outcome · Number, Percentage of participants · Day 100
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 6 |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 |
Overall Survival (OS)
Secondary outcome · Number, Percentage of participants · 2 Years
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 69 |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 |
Event-Free Survival (EFS)
Secondary outcome · Number, Percentage of participants · 2 Years
| Group | Analysed | Value |
|---|---|---|
| FLU, CY, TBI + MGTA-456 Infusion | 16 | 69 |
| BU,FLU, MEL + MGTA-456 Infusion | 2 | 0 |